This study aimed to determine whether prostacyclin (PGI 2 ) functions as an endothelium-26 derived contracting factor (EDCF) in young rat renal arteries, if so, the underlying mechanism(s) 27 and how it alters in pre-hypertensive conditions. Vessels from Wistar-Kyoto (WKY) and pre-28 hypertensive spontaneously hypertensive rats (SHRs) of 25-28 days of age were isolated for 29 functional and biochemical analyses. Result showed that following NO synthase (NOS) 30 inhibition PGI 2 and the thromboxane-prostanoid (TP) receptor agonist U46619 evoked 31 contractions in young WKY renal arteries that were similar to those in pre-hypertensive SHRs. 32
NEW AND NOTEWORTHY 48
Debate exists regarding role of PGI 2 in regulating vasomotor reaction. Here we show that PGI 2 49 acts as an EDCF in young WKY renal arteries and it increases in pre-hypertensive conditions. In 50 its accordance, COX inhibition staring from pre-hypertensive stage was found to show an anti-51 hypertensive effect in young SHRs. 52
INTRODUCTION 54
In hypertension, endothelial dysfunction can be caused by endothelium-derived 55 contracting factors (EDCF) resulting from cyclooxygenase (COX) mediated metabolism of 56 arachidonic acid (12, 13, 42) . In biological tissues, COX exists mainly in two isoforms, namely 57 COX-1 and -2; both of them have been found in vascular endothelium (11, 18, 35, 50) . Also, it 58 has been clear that the metabolism catalyzed by COX isoforms in vascular endothelium mainly 59 produces prostacyclin (PGI 2 ) (14, 18, 24, 35) , which acts on PGI 2 (IP) receptors to mediate 60 vasodilatation and protect vessels from the development of diseases (4, 9, 14, 30, 39) . However, 61 under disease conditions, such as hypertension, IP receptors become dysfunctional, and this 62 together with an excessive production is proposed to result in the endogenously produced PGI 2 63 acting on thromboxane-prostanoid (TP) receptors to function as an EDCF (12, 13, 42) . Indeed, 64 this proposal explains that endothelium-dependent contraction evoked by agonists, such as the 65 endothelial muscarinic receptor agonist ACh, is found in young and adult spontaneously 66 hypertensive rats (SHRs), in ageing, but not in young and/or normal rats (8, 12, 13, 17, 42, 48) . 67
On the other hand, PGI 2 may act on TP receptors independent of vessel types (10, 13, 21, 68 23, 24, 49) . In addition, our results suggest that vasomotor reactions to PGI 2 are modulated by 69 both TP and IP receptors and in some vascular beds with limited functional IP receptors, PGI 2 70 mainly acts on TP receptors to mediate vasoconstrictor activity and function as an EDCF even 71 under normal physiological conditions (23) (24) (25) (26) . However, this idea contradicts the above-72 mentioned findings obtained in rat arteries (8, 12, 13, 17, 42, 48) . Interestingly, IP receptors, 73 which antagonize the effect of PGI 2 on TP receptors, vary considerably among different vascular 74 beds (23). In addition, the amount of PGI 2 evoked by an endogenous agonist in normal arteries is 75 well above the level (3 nM in vessels, such as mouse renal artery) for the agonist to act on TP 76 receptors and evoke vasoconstrictor activity (26). We considered that in certain vessels from 77 young and normal rats, IP receptors may also be scarcely expressed whereby PGI 2 acts mainly on 78 TP receptors and functions as an EDCF that may even increase under pre-hypertensive 79 conditions. Indeed, EDCF has been found in pre-hypertensive or young SHRs (8, 17) ; however, 80 the underlying mechanism(s) and/or its relation to PGI 2 has not been clearly elucidated. Also, 81 whereas COX-1 deficiency (COX-1 -/-), which abolishes not only TxA 2 synthesis in platelets, but 82 also endothelial PGI 2 synthesis that evokes vasoconstrictor effect in some vascular beds, 83 attenuates diabetic hypertension in mice (52), the non-selective COX inhibitor indomethacin has 84 been reported to increase blood pressure (BP) in SHRs with established hypertension or in 85 hypertensive patients, underscoring the vasodilator role of PGI 2 under pathological conditions (3, 86 20, 22, 32) . However, such an inconsistence could possibly result from differences in time of 87 intervention. For example, in the study with diabetic mice COX-1 -/-already exists before the 88 model of disease was established (52). As a result, non-selective COX inhibition starting from 89 pre-hypertensive stage may also beneficially influence the development of hypertension in SHRs, 90 in which PGI 2 could be synthesized via COX-1 and -2 in vascular endothelium (13, 48) . 91 Therefore, in this study renal arteries, where PGI 2 normally evokes potent contraction 92 in other species, such as mice or pigs (25, 26), were isolated from young Wistar-Kyoto rats 93 (WKYs) and pre-hypertensive SHRs (25-28 days) for functional and/or biochemical analyses. 94
Also, experiments were performed to determine how treatment with the non-selective COX 95 inhibitor indomethacin starting from pre-hypertensive stage influences the development of 96 hypertension. 97
MATERIAL AND METHODS 98

Chemicals and solution 99
N ω -nitro-L-arginine methyl ester (L-NAME), ACh, phenylephrine (PE), and the non-100 selective COX inhibitor indomethacin were purchased from Sigma (St Louis, MO, USA). PGI 2 , 101 and other standards of COX-derived products, the COX-1 selective inhibitor FR122047, which 102 has an IC 50 value of 0.03 or 65 μM for COX-1 and COX-2, respectively (31), and the TP 103 receptor antagonist SQ29548, were bought from Cayman Chemical (Ann Arbor, MI, USA). The 104 selective COX-2 inhibitor rofecoxib, which has an IC 50 value of 0.018 or 50 μM for COX-2 and 105 COX-1, respectively (5), was purchased from US Biological (Swampscott, MA, USA). The 106 compositions of physiological salt solution (PSS; pH 7.4 with 95%O 2 -5% CO 2 ) were as follows 107 (in mM): NaCl 123, KCl 4.7, NaHCO 3 15.5, KH 2 PO 4 1.2, MgCl 2 1.2, CaCl 2 1.25, and D-glucose 108 11.5. The 60 mmol/L K + -PSS (K + ) was prepared by replacing an equal molar of NaCl with KCl. 109 L-NAME, PE, ACh, and FR122047 were dissolved in distilled water, while PGI 2 was 110 dissolved in carbonate buffer (50 mM, pH 10.0). SQ29548 and rofecoxib were dissolved in 111 DMSO. All compounds in solvents were at 2,000-fold working concentrations and the final ratio 112 of a solvent (distilled water, carbonate buffer, or DMSO) to working PSS was 0.5/1,000, which 113 doesn't alter the final PH value of working PSS (pH 7.4). 114
Animals and tissue preparation 115
All procedures performed on rats were in conformance with the Guide for the Care and 116
Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication 117 No. 85-23, revised 1996) , and approved by The Institutional Animal Research and Use 118
Committee of Shantou University. 119 WKY or SHR breeding pairs were purchased from Vital River (Beijing, China). Male 120 WKY or SHR progenies 25-28 days of age were included in the study. Rats were killed by CO 2 121 inhalation. For in vitro functional and biochemical analyses, renal arteries were isolated and 122 dissected free of adherent tissues with the help of a binocular microscope. 123
Analyses of vasomotor reaction 124
For analyses of vascular function, main stems of renal arteries from either side were cut 125 into 1 mm rings. Vasomotor reactions were analyzed by isometric force measurement as 126 described previously (25, 26) . Briefly, the vascular ring was mounted between two tungsten 127 wires in an organ bath filled with PSS aerated with 95%O 2 -5% CO 2 and maintained at 37°C. One 128 wire was stationary, whereas the other was connected to an AE801 force transducer (Kronex, 129 Oakland, USA). In some experiments indicated, the endothelium was removed by rotating the 130 vessel ring around the two tungsten wires with the passive tension kept at 100 mg. Thereafter, 131 vessels, including those denuded of the endothelium, were stimulated with 60 mM K + every 15 132 minutes, and the resting tension was adjusted stepwise to an optimal level (~300 mg), at which 133 point the response to 60 mM K + was maximal and reproducible. 134
Unless otherwise indicated, vessels were treated with the NO synthase (NOS) inhibitor L-135 NAME (1 mM), under which the response of arteries appears similar to that of eNOS -/-mice (51). 136
Inhibitors or solvents were added 30 min before the vessel was contracted with an agonist, and 137 was kept in the solution throughout the experiment. The response elicited by an agonist under 138 baseline conditions (relaxed in PSS) was expressed relative to contraction evoked by 60 mM K + 139 (which persists for 10 min and is then relaxed in PSS for the subsequent experiment with an 140 agonist) while that during the contraction evoked by PE (at the amount indicated in PSS) was 141 expressed relative to the value immediately prior to the application of the agent. 142
Assay of 6-keto-PGF 1α 143
Quantification of the PGI 2 metabolite 6-keto-PGF 1α was performed with EIA (26). 144
Briefly, after being rinsed of blood components, renal arteries (vessels from both sides were 145 pooled for each single experiment) were incubated with PSS at 37 o C for 30 min, followed by 146 exposure to PSS (150 μl) and ACh (10 μM) in 150 μl PSS (37 o C) for 15 min each. In some 147 experiments, FR122047 (1 μM) was added to incubating buffer, and was kept in the buffer 148 throughout the experiment. Thereafter, vessels were taken out, and the reaction solutions were 149 diluted with EIA buffer (1:50), and 100 μl of final solution was used for 6-keto-PGF 1α 150 measurement, according to instructions of the manufacturer (26). The amount of 6-keto-PGF 1α 151 was expressed in ng per mg of wet tissue. 152
In addition, the signal of 6-keto-PGF 1α (molecular mass of 370; M370) in pre-153 hypertensive SHR renal arteries was further verified by HPLC-mass spectroscopy (HPLC-MS), 154 with which peaks of other COX-derived products (thromboxane B 2 ; TxB 2 : M370 with a retention 155 time different from that of 6-keto-PGF 1α , PGE 2 and PGD 2 : M352, or PGF 2α : M354) could also 156 be monitored, although they may have varied sensitivities (50). Briefly, after being incubated 157 with PSS at 37 o C for 30 min, pre-hypertensive SHR renal arteries (pooled from 12 rats) were 158 stimulated with ACh (10 μM) in 1,000 μl PSS for 15 min. The extraction of 6-keto-PGF 1α and its 159 HPLC-MS detection were performed as described previously (50). 160
161
Western blot 162
Expressions of COX-1, PGIS, TP receptors, IP receptors, and β-actin (internal controls) 163 were detected by Western blot. Anti-COX-1 (polyclonal; rabbit; 1:1,000), Anti-PGIS 164 (polyclonal; rabbit; 1:2,000), anti-TP receptor (polyclonal; rabbit; 1:2,000), and anti-IP receptor 165 (polyclonal; rabbit; 1:2,000) antibodies were purchased from Cayman Chemical, while anti-β-166 actin antibody (polyclonal; rabbit; 1:2,000) was bought from Santa Cruz Biotechnology (Santa 167
Cruz, CA). Immunocomplexes were visualized with reaction solution from an ECL plus kit 168 (Amersham, Buckinghamshire, UK), and detected using Kodak X-ray film (XBT-1; Xiamen, 169 China). 170
Indomethacin treatment 171
In some experiments, pre-hypertensive SHRs were treated with indomethacin (dissolved 172 in ethanol at 2 mg/ml and then diluted in drinking water at 19.5 μg/ml) in a daily dosage of 1.5 173 mg/kg or with solvent for 60 days starting from the 26 th day after birth. Systolic BP (SBP) was 174 measured the day prior to indomethacin treatment and then once every five days thereafter, using 175 a non-invasive computerized tail-cuff system (ALC-NIBP, ALCBIO; Shanghai, China). Rats 176 were accustomed to the tail-cuff blood pressure measurements for 3 days before the first 177 measurement and then 1 day before each measurement. SBP was obtained with 3 consecutive 178 measurements that showed a similar value. One or two months after the start of indomethacin 179 treatment, rats were killed (with CO 2 inhalation) and the heart and kidneys were obtained to 180 evaluate the heart or kidneys to body weight ratio. In addition, such parameters of age-matched 181
WKYs on normal drink were similarly obtained for contrasts to indicate the deviation of 182 pathologies in indomethacin-treated or untreated SHRs. 183
Data analyses 184
Values were expressed as means ± SEM from n numbers or pools of vessels from 185 different animals. The normality of data sets was confirmed with Kolmogorov-Smirnov test. 186
Thereafter, a Student's t-test (unpaired; two tails) or ANOVA (one way or two way) followed by 187
Bonferroni's post-hoc test was performed on data sets with equal variance or those with variance 188 homogeneity achieved by transformation with logarithm for statistical analyses. For those with 189 homogeneity of variance un-attainable, analyses were performed with Friedman's test followed 190 by Dunn's post hoc test instead. P<0.05 was considered to be statistically significant. 191
RESULTS 193
Vasomotor reaction to PGI 2 or the TP receptor agonist U46619 194 Firstly, the direct response of renal arteries from young WKYs and/or pre-hypertensive 195 SHRs evoked by PGI 2 was examined. As shown in Fig 1A, starting from 0.3 μM, PGI 2 evoked a 196 concentration-dependent contraction in L-NAME-treated young WKY renal arteries, which is 197 comparable to that of pre-hypertensive SHRs. Interestingly, the TP receptor antagonist SQ29548 198 (10 μM) diminished the contraction in both young WKY and pre-hypertensive SHR renal 199 arteries ( Fig 1A) . Also, PGI 2 was noted to evoke contraction in NOS-uninhibited (L-NAME 200 untreated) WKY renal arteries, although to a lesser extent (Fig 1A) . Moreover, in such (L-201 NAME untreated) vessels pre-contracted with PE (3 μM; to achieve a sustained contraction 110% that of 60 mM K + ) PGI 2 (0.1-1 μM) did not evoke any relaxation after TP receptor 203 antagonism ( Fig 1B top; n=3) , which was in contrast to a noticeable graded relaxation (-25.1 ± 204
1.9% at 1 μM; n=3) that was obtained in similarly treated thoracic aortas from same rats (Fig 1B,  205 bottom), where IP receptors had been suggested to be functional previously (12, 13, 44) . 206
At the same time, the TP receptor agonist U46619 (0.003-0.3 μM) evoked contractions 207 that were again comparable between L-NAME-treated young WKY and pre-hypertensive SHR 208 renal arteries (Fig 1C) . Interestingly, in such young WKY or pre-hypertensive SHR vessels (Fig 209 1D middle and bottom traces, respectively; n=3 for each) additionally treated with SQ29548 (10 210 μM), maximal concentration of U46619 (0.3 μM), which evoked a contraction of 135 ± 11.3% 211 (n=3) in young WKY vessels treated with L-NAME alone (Fig 1D top) would stimulate the synthesis of native PGI 2 (13, 24), in young WKY and/or pre-hypertensive 217 SHR renal arteries were examined. As shown in Figure 2A (top trace), in young WKY renal 218 arteries pre-contracted with 3 μM PE (to achieve a sustained contraction 90-110% that evoked 219 by 60 mM K + ), ACh (10 μM) evoked a relaxation, which was however blunted by a biphasic 220 force development. Interestingly, such a biphasic force was absent in vessels that had been 221 treated with 10 μM of the non-selective COX inhibitor indomethacin (Fig 2A, bottom) . In 222 addition, in young WKY renal arteries treated with L-NAME (Fig 2B, bottom) but not in those 223 of controls untreated (Fig 2B top) , ACh (10 μM) evoked contraction under baseline conditions, 224 which further increased in those of pre-hypertensive SHRs (106.2 ± 7.8% vs. 75.6 ± 4.67; n=6, 225
P<0.01). 226
Moreover, we noted that the COX-1 inhibitor FR122047 (1 μM) or the TP receptor 227 antagonist SQ29548 (10 μM) but not the COX-2 inhibitor rofecoxib (1 μM) diminished the 228 contraction evoked by ACh (10 μM) in either young WKY or pre-hypertensive SHR arteries 229 treated with L-NAME (Fig 2C) . Also, in such treated young WKY or pre-hypertensive SHR 230 vessels that had been denuded of endothelium, ACh was unable to induce any contraction (Fig  231   2D top and middle traces, respectively, n=3 for each, bottom is a control response from pre-232 hypertensive SHRs with endothelium). 233
PGI 2 synthesis evoked by ACh in WKY and SHR renal arteries 234
Therefore, the ability of ACh to evoke in vitro production of PGI 2 in young WKY renal 235 arteries, and how it alters in pre-hypertensive SHRs were examined. As shown in Fig 3A, in both  236 young WKY and pre-hypertensive SHR renal arteries, ACh (10 μM) evoked an increase in levels 237 of the PGI 2 metabolite 6-keto-PGF 1α as against basal conditions (in PSS only, un-stimulated with 238 ACh). Interestingly, either the basal 6-keto-PGF 1α or that after ACh stimulation was higher in 239 pre-hypertensive SHR than in young WKY arteries (Fig 3A) . Also, the COX-1 inhibitor 240 FR122047 (1 μM) abolished the increase of 6-keto-PGF 1α evoked by ACh, and reduced the basal 241 level in vessels from either rat strain (Fig 3A) . Indeed, the signal of 6-keto-PGF 1α of pre-242 hypertensive SHR renal arteries could be clearly seen with HPLC-MS, while those of others, 243
including TxB 2 , PGF 2α , PGE 2 and PGD 2 , were hardly discernable (Fig 3B top) , possibly due to a 244 minor amount of production (13, 24, 45) and/or a lower sensitivity to the method as revealed by 245 signals of standard compounds with the amount indicated (Fig 3B bottom) . 246
Expression of COX-1, PGIS, TP and IP receptors 247
To explore the molecular bases for the above observations, expressions of COX-1, PGIS, 248 TP, IP receptors, and β-actin (as internal controls) in young WKY and pre-hypertensive SHR 249 renal arteries were examined with Western blot. As shown in Fig 4 (A & B) , COX-1, PGIS and 250 TP receptor proteins were clearly detected; however, no significant difference was found 251 between their β-actin normalized levels of young WKY and pre-hypertensive SHR arteries. In 252 addition, IP receptors, which were clearly seen in renal medullas and to a lesser degree in the 253 thoracic aorta, were not detected in renal arteries from same young WKYs (Fig 4C) . In a similar 254 manner to those of WKYs, IP receptors were detected in renal medullas, but not in renal arteries 255 of pre-hypertensive SHRs (Fig 4D) . This was in contrast to the protein of β-actin, which was 256 detected with a higher abundance in renal arteries than in medullas of either rat strain (Fig 4D) . 257 heart to body weight in SHRs (compared to that of WKYs) was alleviated in indomethacin-265 treated SHRs (Table 1) . On the other hand, the kidney enlargement or increased ratio of kidney 266 to body weight in indomethacin-treated SHRs was aggravated by the end of 1 st month of 267 treatment (Table 1) . 268
DISCUSSION 270
In this study, we showed that both PGI 2 and the TP receptor agonist U46619 evoked 271 contractions in young WKY renal arteries, which were comparable to those of pre-hypertensive 272 SHRs. Meanwhile, the endothelial muscarinic receptor agonist ACh was noted to evoke a 273 vasoconstrictor response and a production of the PGI 2 metabolite 6-keto-PGF 1α ; both of them 274 were sensitive to COX or COX-1 inhibition, but higher in pre-hypertensive SHR than in young 275 WKY renal arteries. Also, TP receptor antagonism, which inhibited the contraction, did not 276 result in any relaxation to PGI 2 . Moreover, we found that treatment with the non-selective COX 277 inhibitor indomethacin starting from the pre-hypertensive stage blunted SBP elevation and 278 reduced the heart to body ratio in SHRs. These results not only demonstrate an EDCF action of 279 COX-1-derived PGI 2 in young WKY renal arteries that increases in pre-hypertensive conditions, 280 but also suggest a beneficial effect of COX inhibition on young SHRs 281 An important observation of the present study was that in L-NAME-treated young WKY 282 renal arteries the extraneously applied PGI 2 evoked potent contraction that was sensitive to TP 283 receptor antagonism. It should be noted that PGI 2 evokes contraction in L-NAME-untreated 284 vessels, although to a lesser extent, possibly due to the effect of basal NO production as 285 suggested elsewhere previously (13, 25). Notably, after TP receptor antagonism PGI 2 was unable 286 to evoke any relaxation even under NOS-uninhibited conditions. These results imply a major 287 vasoconstrictor action of PGI 2 mainly via TP receptors, possible due to scarcity of activity 288 derived from vasodilator IP receptors. In support of this idea, IP receptors, which were clearly 289 seen in renal medullas, and to a lesser degree in the thoracic aorta, were not detected by Western 290 blot in renal arteries. Moreover, we noted that the relaxation evoked by endothelial muscarinic 291 receptor agonist ACh was blunted by a force development that was removed by COX inhibition, 292 which suggests the presence of a COX-mediated EDCF activity in the dilator response evoked by 293 the gent that is mainly mediated by endothelial NO (51). Indeed, in the presence of the NOS-294 inhibitor L-NAME, ACh evoked contraction under baseline (un-pre-contracted) conditions, 295 which was sensitive to COX-1 inhibition, TP receptor antagonism, or endothelial denudation as 296 we previously noted in normal mouse or porcine arteries (24, 25). Moreover, 6-keto-PGF 1α 297 measurements showed that ACh evoked a COX-1-mediated native synthesis of PGI 2 , whose 298 amount would be well above the initial level (0.3 μM) of the agent to evoke vasoconstrictor 299 activity (1 ng/mg 6-keto-PGF 1α equals 2.7 μmol PGI 2 per kg of vessel tissue). These results 300 further point to the fact that PGI 2 , which is produced mainly via COX-1-mediated metabolism, 301 acts as an EDCF in young WKY renal arteries. 302
Moreover, the contraction evoked by ACh under NOS-inhibited conditions was higher in 303 pre-hypertensive SHR renal arteries than that of WKYs, which suggests an increased EDCF 304 activity under the pathological condition. Again, the contraction to ACh in the pre-hypertensive 305 SHR vessels was largely removed by COX-1 inhibition, by TP receptor antagonism, or by 306 endothelial denudation. Interestingly, the contraction to PGI 2 or the TP receptor agonist U46619 307 together with results from Western blot revealed that either the expression or function of TP 308 receptors were unaltered in pre-hypertensive renal arteries. Thus, the above increased EDCF 309 activity in pre-hypertensive SHRs doesn't appear to result from the effector receptor level, but 310 rather from amounts of EDCF produced. In its consistency, the amount of 6-keto-PGF 1α (whose 311 signal was confirmed by HPLC-MS) evoked by ACh was higher in pre-hypertensive SHR than 312 in young WKY vessels, and it was again abolished by COX-1 inhibition. Therefore, in pre-313 hypertensive SHR renal arteries COX-1 is also a major mediator for the synthesis of PGI 2 , which 314 acts as an EDCF and increases under the pathological condition. In contrast, COX-2 does not 315 appear to have a role in either young WKY or pre-hypertensive SHR renal arteries. This could be 316 clearly revealed by the ineffectiveness of its inhibitor rofecoxib on ACh-induced contractions. 317
Also of interest was that the increase in both SBP and ratio of heart to body weight was 318 alleviated in indomethacin-treated SHRs. This may suggest an anti-hypertensive effect of non-319 selective COX inhibition starting from pre-hypertensive stage and is well in agreement with the 320 EDCF-like action of PGI 2 in critical vessels, such as renal arteries, especially under pre-321 hypertensive conditions. In fact, EDCF activity has also been noted in intra-renal or mesenteric 322 arteries of pre-hypertensive and/or young SHRs (8, 17) . In addition, the role of PGI 2 as an EDCF 323 has been suggested in vessels of SHRs with established hypertension (13, 42) . In the present 324 study, we further showed that IP receptors are scarcely expressed in young WKY renal arteries, 325 whereby PGI 2 evokes vasoconstrictor activity and function as an EDCF under physiological 326 condition, concurring with results we previously noted in mice and pigs (23) (24) (25) 27) . Also, while 327 COX-2 is suggested to mediate EDCF activity in many hypertensive rat arteries (29, 40, 43, 45, 328 47, 48), our results suggest that COX-1 is responsible for such activity in rat renal arteries, 329 similar to results observed in aortas from adult SHRs (13). Moreover, our results suggest that in 330 the pre-hypertensive renal arteries COX-1-derived PGI 2 increases and it may lead to an enhanced 331 EDCF activity, an abnormality that is commonly found under hypertension or disease conditions 332 (13, 43, 45, 46) . However, the contribution of this increase of EDCF activity to the development 333 of hypertension still needs further evaluation, given the un-sustained property of the contraction 334 evoked by the endothelial agonist ACh and the fact that other COX-derived activities, including 335
TxA 2 synthesis in platelets, also increase BP or adversely influence vascular and renal functions 336 (1, 15, 33) . 337
At the same time, the pre-hypertensive SHRs still became hypertensive (SBP >140 338 mmHg) during the 2 nd month of indomethacin treatment. Indeed, a similar phenomenon has been 339 observed with another COX inhibitor aspirin (41), although the agent affects more on platelets 340 than on vascular endothelium (16, 38) . Thus, the anti-hypertensive effect of COX inhibition 341 appears to be age-dependent, which might reflect the complicity of mechanisms or involvement 342 of other pro-hypertensive factors, such as the renin-angiotensin system, in the disease condition 343 (7, 28) . In addition, indomethacin may cause damages to renal function (19, 36), which may 344 probably explain a pro-hypertensive effect of the agent in SHRs with established hypertension or 345 in hypertensive patients (3, 20, 22, 32) . Interestingly, in the present study, an aggravation of 346 kidney enlargement was observed at the end of 1 st month of indomethacin treatment. However, at 347 this stage the alleviation of increased SBP and ratio of heart to body weight was most evident. As 348 a result, how the renal effect of indomethacin is related to the age-dependent anti-hypertensive 349 effect of COX inhibition still requires further investigation. In addition, whereas the contraction 350 and PGI 2 synthesis evoked by ACh was increased, COX-1 and PGIS levels in pre-hypertensive 351 SHR renal arteries were comparable to those of WKYs. Such an inconsistence has also been 352 observed in previous studies, and hence could possibly result from a functional modification of 353 enzymes (13, 42) , although the precise underlying mechanism(s) remains to be further elucidated. 354 Also, one might have noted that conditions of our functional analyses, such as O 2 355 concentration, are different from those of in vivo conditions and that our experiments are not 356 performed on resistance arteries, arousing concerns on the applicability of our present studies. 357
However, it needs to be pointed out that COX-mediated endothelium-derived vasoconstrictor 358 activity has been known to exist in humans under in vivo conditions (2, 6, 43) . In addition, PGI 2 359 is an EDCF in porcine interlobular renal arteries (25), and this agonist is also found to act on TP 360 receptors in similar vessels of humans although a vasodilator response via IP receptors is 361 observed at low concentrations (10). Indeed, infusions of subvasodepressor doses of PGI 2 has 362 been found to cause lower glomerular filtration rate in Munich-Wistar rats, although this was 363 considered to be an effect derived from angiotensin II (37). Thus, PGI 2 can also act as an EDCF 364 under in vivo conditions, and/or its activity via TP receptors may constitute an integral part of 365 endothelium-mediated regulatory mechanisms despite variation may exist among species. In 366 addition, we found that in the presence of TP receptor antagonist SQ29548, which completely 367 abolished the contraction evoked by the receptor agonist U46619, a minor vasoconstrictor 368 response to PGI 2 or ACh still existed, concurring with results observed previously (34). As a 369 result, further studies might also be needed to determine whether there is an additional 370 mechanism(s), involved in the EDCF-like action of PGI 2 in rat arteries. 371
In summary, our results demonstrate that due to scarcity of functional IP receptors PGI 2 , 372 which is mainly derived from COX-1-metabolism, acts as an EDCF in the young WKY renal 373 arteries, which may increase under pre-hypertensive conditions. Also, our data revealed that non-374 Table 1 : Effects of indomethacin treatment on heart and kidney sizes in SHR FIGURE LEGENDS 553 WKY and pre-hypertensive SHR vessels treated with L-NAME and SQ29548 (SQ). Top is a 568 control response obtained in WKY RAs treated only with L-NAME. 569 
